Published in Clinical Oncology Week, July 26th, 2010
minimally invasive permanent prostate brachytherapy management of prostate cancer, has announced that it has signed an agreement to distribute Theragenics Corporation TheraSeed® palladium-103 brachytherapy seeds.
Under the terms of the agreement, Oncura will exclusively sell the TheraSeed palladium-103 seed, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through May 31, 2013 and provides for additional one-year terms upon mutual agreement of the parties.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.